[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PreventionFirst intervention group: Injecting one dose of 1 ml solution of SpikoGen\u00ae vaccine containing recombinant SARS-CoV-2-S protein and Advax\u2122 and CpG adjuvants in the non-dominant arm on days 0 and 21 in individuals aged 12-40", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PreventionSecond intervention group: Injecting one dose of 0.5 ml solution of SpikoGen\u00ae vaccine containing recombinant SARS-CoV-2-S protein and Advax\u2122 and CpG adjuvants in the non-dominant arm on days 0 and 21 in individuals aged 5-12", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "1mL;2;Days0-21;IM;12-18 years old", "treatment_id": 335, "treatment_name": "Covax-19", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "1mL;2;Days0-21;IM;18-40 years old", "treatment_id": 335, "treatment_name": "Covax-19", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PreventionIntervention group: Injecting one dose of 1 ml solution of SpikoGen\u00ae vaccine containing recombinant SARS-CoV-2-S protein and Advax\u2122 and CpG adjuvants in the non-dominant arm on days 0 and 21", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]